Wilms' Tumor Clinical Trials

A listing of Wilms' Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 53 clinical trials
Featured trial
AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

  • 08 Nov, 2020
  • 1 location
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger

  • 28 Jan, 2021
  • 1 location
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

  • 14 Mar, 2021
  • 1 location
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Trial participants are randomised within 14 days after liver transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus® (test arm) or Advagraf® (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals …

  • 30 May, 2022
  • 15 locations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms

  • 28 Oct, 2022
  • 95 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first …

high-risk neuroblastoma
monoclonal antibodies
bone marrow procedure
colony stimulating factor
  • 07 Oct, 2022
  • 23 locations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

beta human chorionic gonadotropin
cns metastases
cytotoxic chemotherapy
solid tumour
  • 25 Oct, 2022
  • 108 locations
DWI in the Diagnosis of Histological Types of Nephroblastoma in Children

). The data is entered into the database and the relationship between ADC values and histological degrees of malignancy of nephroblastoma is investigated

  • 02 Apr, 2021
  • 1 location
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

pancreatic adenocarcinoma
cancer of the ovary
measurable disease
  • 04 Oct, 2022
  • 2 locations
Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

(bilateral Wilms tumor) and specific involved surgical margins yielding no reduction in the high control rates seen with more traditional flank / whole kidney fields. Exploratory Objectives

tumor cells
chemotherapeutic agents
  • 07 Oct, 2022
  • 1 location